Helmut Gadner: A Charismatic Leader, Visionary, and Pioneer in Pediatric Oncology.

Helmut Gadner, a world-famous pediatric hematologist-oncologist, dedicated his professional life to researching pediatric cancer and advancing care for affected children, adolescents, and their families. Starting his career in the team of Hansjörg Riehm, the father of the ever-most successful BFM (abbreviation of the city names of the founding institutions, Berlin-Frankfurt-Münster) treatment concept of pediatric leukemia, the young Dr. Gadner became a passionate soldier in the fight against pediatric cancer.

Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: A report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS).

Background: Osteosarcoma may arise as a secondary malignancy following rhabdomyosarcoma (RMS). We utilized the Cooperative Osteosarcoma Study Group (COSS) database to better understand this association.

Patients And Methods: The COSS database (1980-05/2023) was searched for patients whose osteosarcoma was preceded by RMS.

Beyond 5-year survival. A report from the Cooperative Osteosarcoma Study Group (COSS).

Purpose: Prognostic factors have been well described for osteosarcoma, but analyses evaluating the further course of long-term survivors are lacking. We used the large database of the Cooperative Osteosarcoma Study Group (COSS) to perform such an analysis.

Patients And Methods: The COSS database 1980-04/2019 was searched for 5-year survivors of primary high-grade central osteosarcoma of the extremities or trunk.